يستعمل دواء بيميتريكسيد اكورد 500مجم امبول حقن وريدpemetrexed-accord 500mg i.v. vial antineoplastic antineoplastic

it is approved by the fda in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (nsclc) a specific type of nsclc. it is not indicated for patients who have a different type of nsclc called squamous cell. - -it is approved by the fda for the treatment of patients with advanced nonsquamous non-small cell lung cancer (nsclc) a specific type of nsclc to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. it is not indicated for patients who have a different type of nsclc called squamous cell. - -it is approved by the fda as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (nsclc) a specific type of nsclc after prior chemotherapy. it is not indicated for patients who have a different type of nsclc called squamous cell. it is a treatment for malignant pleural mesothelioma. - -dose: once every 21 days.